Skip to Content

Pasireotide use while Breastfeeding

Drugs containing Pasireotide: Signifor, Signifor LAR

Medically reviewed by Drugs.com. Last updated on Dec 10, 2020.

Pasireotide Levels and Effects while Breastfeeding

Summary of Use during Lactation

The excretion of pasireotide into breastmilk has not been studied. However, because it has a high molecular weight of 1047 daltons it is likely to be poorly excreted into breastmilk and it is a peptide that is likely digested in the infant's gastrointestinal tract. It is unlikely to reach the clinically important levels in infant serum. However, the manufacturer states that nursing mothers should not use pasireotide.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Octreotide

Substance Identification

Substance Name

Pasireotide

CAS Registry Number

396091-73-9

Drug Class

  • Breastfeeding
  • Lactation
  • Hormones
  • Somatostatin Analogs and Derivatives

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.